Table 4.
Summary of median overall survival (OS) and progression-free survival (PFS) between dacomitinib and placebo in NCIC-BR-26
| Dacomitinib
|
Placebo
|
HR | 95% CI | P-value | |||
|---|---|---|---|---|---|---|---|
| Median | 95% CI | Median | 95% CI | ||||
| Median OS (months) | |||||||
| All | 6.83 | 6.08–7.49 | 6.31 | 5.32–7.52 | 1.00 | 0.83–1.21 | 0.506 |
| KRAS WT | 7.00 | 6.01–8.21 | 5.19 | 4.53–7.00 | 0.79 | 0.61–1.03 | 0.043 |
| EGFR-mutant | 7.23 | 6.08–8.61 | 7.52 | 4.99–9.49 | 0.98 | 0.67–1.44 | 0.461 |
| EGFR WT | 6.93 | 5.82–8.08 | 5.55 | 4.60–7.20 | 0.93 | 0.71–1.21 | 0.283 |
| KRAS-mutant | 5.82 | 4.11–7.23 | 8.28 | 4.27–14.90 | 2.10 | 1.05–4.22 | 0.984 |
| Median PFS (months) | |||||||
| All | 2.66 | 1.91–3.33 | 1.38 | 0.99–1.74 | 0.66 | 0.55–0.79 | <0.0001 |
| KRAS WT | 3.06 | 1.91–3.55 | 1.05 | 0.9–1.71 | 0.58 | 0.46–0.73 | |
| EGFR-mutant | 3.52 | 2.53–3.68 | 0.95 | 0.89–1.64 | 0.48 | 0.35–0.66 | |
| EGFR WT | 1.91 | 1.77–2.79 | 1.63 | 0.99–1.81 | 0.75 | 0.59–0.95 | |
| KRAS-mutant | 1.61 | 0.92–1.87 | 1.86 | 0.95–2.33 | 1.34 | 0.78–2.29 | |
Note: Data from Ellis et al.28
Abbreviations: CI, confidence interval; HR, hazard ratio.